COPD Explained: Breathlessness, Smoking, and Lung Risk

Educational disclaimer: This article provides general health education based on published clinical guidelines and research. It is not medical advice and cannot diagnose, prescribe, or replace a consultation with a qualified clinician. Do not start, stop, or change any medication or therapy based on this article. If you have concerns about breathing difficulties or lung health, speak with your doctor.

Centrilobular emphysema — a hallmark of COPD. The enlarged airspaces result from destruction of alveolar walls, reducing the surface area available for gas exchange and causing air trapping.

What COPD Is

Chronic obstructive pulmonary disease (COPD) is a common, preventable lung condition characterised by persistent respiratory symptoms and airflow limitation that is not fully reversible. It is a progressive disease — meaning it tends to worsen over time — but its progression can be significantly slowed with appropriate interventions.

COPD encompasses two main patterns of lung damage that often coexist:

• Chronic bronchitis — inflammation and narrowing of the airways with excess mucus production, causing persistent cough and sputum.
• Emphysema — destruction of the alveoli (tiny air sacs where gas exchange occurs), reducing the lung's surface area and causing air trapping.

COPD is the third leading cause of death worldwide, with an estimated 480 million people affected globally. It is a major cause of disability and healthcare utilisation, yet remains underdiagnosed — many people live with significant airflow limitation without knowing it.

How the Lungs Are Affected

In healthy lungs, air flows freely through the airways into millions of elastic alveoli, where oxygen passes into the blood and carbon dioxide is released. In COPD, chronic exposure to harmful particles and gases triggers a cascade of damage:

• Airway inflammation — the airways become chronically inflamed, their walls thicken, and smooth muscle contracts, narrowing the passages.
• Mucus hypersecretion — enlarged mucus glands produce excess sputum that further obstructs airflow and provides a breeding ground for infections.
• Small airway destruction — the smallest airways (bronchioles) are progressively destroyed and lost, which is now recognised as the major site of airflow limitation in COPD.
• Alveolar destruction (emphysema) — the walls between alveoli break down, creating larger but fewer air sacs with reduced surface area for gas exchange.
• Loss of elastic recoil — the lungs lose their ability to spring back during exhalation, causing air to become trapped (hyperinflation).
• Gas exchange impairment — as disease progresses, oxygen levels fall (hypoxaemia) and eventually carbon dioxide may accumulate (hypercapnia).

These changes are largely irreversible once established, which is why prevention and early intervention are so important.

Why Breathlessness and Exacerbations Matter

The hallmark symptom of COPD is breathlessness (dyspnoea) — initially noticed only during physical exertion, but progressively limiting daily activities as the disease advances. Other common symptoms include chronic cough, sputum production, wheezing, and chest tightness.

Exacerbations — acute episodes of worsening symptoms beyond normal day-to-day variation — are particularly important because they:

• Accelerate lung function decline — each exacerbation causes additional damage that may not fully recover.
• Reduce quality of life — recovery can take weeks, and some patients never return to their pre-exacerbation baseline.
• Increase mortality risk — severe exacerbations requiring hospitalisation carry significant short-term and long-term mortality risk.
• Drive healthcare costs — hospitalisations for COPD exacerbations are a leading cause of healthcare expenditure.
• Predict future events — the strongest predictor of future exacerbations is a history of previous exacerbations.

People who experience two or more moderate-to-severe exacerbations per year are classified as "frequent exacerbators" — a phenotype associated with worse outcomes and more intensive management needs.

Who Is At Higher Risk

• Cigarette smoking — the most important risk factor in high-income countries, accounting for approximately 80% of COPD cases. Risk increases with pack-years (amount × duration). However, not all smokers develop COPD, and not all COPD is caused by smoking.
• Passive (secondhand) smoke — chronic exposure to others' tobacco smoke increases COPD risk, particularly in childhood.
• Biomass fuel smoke — burning wood, animal dung, crop residues, or coal for cooking and heating is a major cause of COPD in low- and middle-income countries, disproportionately affecting women.
• Occupational exposures — dusts (mining, construction, agriculture), chemical fumes, and vapours contribute to COPD even in non-smokers. Occupational COPD is underrecognised.
• Outdoor air pollution — particulate matter (PM2.5), nitrogen dioxide, and other pollutants contribute to COPD development and trigger exacerbations.
• Alpha-1 antitrypsin deficiency — the best-characterised genetic risk factor. This inherited condition causes early-onset emphysema, particularly in smokers. Testing should be considered in people who develop COPD before age 45 or with a family history.
• Impaired lung development — factors that reduce maximum attained lung function (prematurity, low birth weight, childhood respiratory infections, childhood asthma, malnutrition) increase the risk of COPD later in life, even without accelerated decline.
• Age — COPD prevalence increases with age, reflecting cumulative exposure and natural lung function decline.
• Tuberculosis — previous TB is a significant risk factor for airflow obstruction, particularly in high-burden countries.

COPD is not exclusively a "smoker's disease." Globally, a substantial proportion of COPD occurs in never-smokers, particularly in regions with high biomass fuel use and occupational exposures.

How Clinicians Diagnose COPD

COPD should be considered in anyone with breathlessness, chronic cough, or sputum production — especially with a history of exposure to risk factors. However, spirometry is required to confirm the diagnosis.

Spirometry

Spirometry is a simple breathing test that measures how much air you can blow out and how quickly:

• FEV1 — the volume of air you can forcefully exhale in one second.
• FVC — the total volume of air you can forcefully exhale.
• FEV1/FVC ratio — in COPD, this ratio is reduced (< 0.70 after bronchodilator), confirming airflow obstruction that is not fully reversible.

The test is performed before and after inhaling a bronchodilator medication. If the obstruction persists after the bronchodilator (post-bronchodilator FEV1/FVC < 0.70), COPD is confirmed. This distinguishes COPD from asthma, where obstruction is typically fully reversible.

Assessment Beyond Spirometry

• Symptom severity — assessed using tools like the mMRC dyspnoea scale or COPD Assessment Test (CAT).
• Exacerbation history — number and severity of exacerbations in the past year.
• GOLD classification — combines spirometric severity (grades 1–4 based on FEV1) with symptom burden and exacerbation risk to guide treatment.
• Imaging — chest X-ray or CT scan helps exclude other diagnoses (lung cancer, bronchiectasis, heart failure) and assess emphysema distribution, but is not required for diagnosis.
• Blood eosinophils — may help guide decisions about inhaled corticosteroid use.

Important: a single spirometry reading in isolation does not diagnose COPD. Clinical context, symptoms, risk factor history, and exclusion of alternative diagnoses are all part of the assessment.

What Usually Helps Reduce Risk

These are population-level approaches supported by clinical evidence. Discuss what is appropriate for your situation with your clinician.

• Smoking cessation — the single most important intervention at any stage of COPD. Quitting slows the rate of lung function decline toward that of a never-smoker. It is never "too late" to benefit from stopping. Support (behavioural counselling, pharmacotherapy) significantly improves quit rates.
• Reducing indoor air pollution — improved cookstoves, better ventilation, and cleaner fuels reduce exposure to biomass smoke.
• Occupational protection — dust control measures, proper ventilation, and respiratory protective equipment in high-risk workplaces.
• Vaccination — influenza vaccination reduces exacerbations and COPD-related hospitalisations. Pneumococcal and COVID-19 vaccination are also recommended for people with COPD.
• Physical activity — regular physical activity is associated with reduced exacerbation risk, slower lung function decline, and better quality of life. Even modest increases in activity are beneficial.
• Reducing outdoor air pollution exposure — avoiding heavy traffic areas during high-pollution days, monitoring air quality indices, and supporting clean air policies.
• Early detection — spirometry screening in symptomatic individuals with risk factor exposure allows earlier intervention before significant lung function is lost.

What Clinicians May Discuss

This is an overview of management approaches — not a recommendation to start or change any treatment. All decisions require individual clinical assessment.

• Bronchodilators — inhaled medications that relax airway muscles and improve airflow. Long-acting bronchodilators (LABA, LAMA) are the mainstay of COPD pharmacotherapy.
• Inhaled corticosteroids (ICS) — may be added for patients with frequent exacerbations and/or elevated blood eosinophils. Not recommended for all COPD patients.
• Pulmonary rehabilitation — structured exercise and education programmes that improve breathlessness, exercise capacity, and quality of life. One of the most effective interventions in COPD, yet underutilised.
• Oxygen therapy — long-term supplemental oxygen improves survival in patients with severe resting hypoxaemia. Requires clinical assessment and monitoring.
• Exacerbation action plans — written plans that help patients recognise worsening symptoms early and take appropriate steps (including when to seek urgent care).
• Surgical options — lung volume reduction surgery, bullectomy, or lung transplantation may be considered for selected patients with severe disease who meet specific criteria.

Do not start, stop, or adjust any inhaler, medication, or oxygen therapy based on this article. COPD management is individualised and requires ongoing clinical monitoring.

When To Seek Urgent Help

COPD exacerbations can become life-threatening. Seek immediate medical attention if you or someone you know experiences:

• Severe or rapidly worsening breathlessness — especially if it does not respond to usual reliever inhaler or is significantly worse than baseline.
• Blue lips or fingertips (cyanosis) — indicates dangerously low oxygen levels.
• Confusion, drowsiness, or difficulty staying awake — may indicate severe hypoxaemia or carbon dioxide buildup (hypercapnia) — a medical emergency.
• Chest pain — requires urgent evaluation to exclude pneumothorax (collapsed lung), pulmonary embolism, or heart attack.
• Inability to speak in full sentences — indicates severe respiratory distress requiring emergency care.
• High fever with worsening cough and breathlessness — may indicate pneumonia complicating COPD.

If in doubt, call emergency services. It is always better to seek help early than to wait until breathing becomes critical.

Questions To Ask Your Doctor

• I have a persistent cough and breathlessness — should I have spirometry to check for COPD?
• What stage is my COPD, and what does that mean for my daily life?
• Am I using my inhalers correctly? Could my technique be improved?
• Would pulmonary rehabilitation help me? How do I access it?
• What should I do at the first sign of an exacerbation?
• Should I be tested for alpha-1 antitrypsin deficiency?
• What vaccinations should I have to reduce my exacerbation risk?
• How can I stay physically active safely with my level of breathlessness?

Sources

• GOLD 2024. Global Strategy for the Diagnosis, Management, and Prevention of COPD. goldcopd.org
• WHO. Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet. who.int
• CDC. COPD. cdc.gov
• NHLBI/NIH. COPD. nhlbi.nih.gov
• NHS. Chronic Obstructive Pulmonary Disease (COPD). nhs.uk
• NICE Guideline NG115. COPD in over 16s: diagnosis and management. nice.org.uk
• American Lung Association. COPD. lung.org